Significantly higher. It has been announced that a strategic partnership agreement has been signed with AGC ＜5201＞ in the cell therapy drug CDMO (contract manufacturing of pharmaceuticals, etc., development outsourcing/agency of manufacturing methods) business. In addition to working on the exchange and development of human resources involved in manufacturing and quality between the two companies, Medinet's development and manufacturing capabilities will be complemented at AGC's domestic and international bases. First, AGC will accumulate knowledge in Japan through Medinet's support, and it is said that preparations will proceed for the start of cell therapy drug CDMO services at the Yokohama base.
ＭＤＮＴ---大幅高、AGCと細胞治療薬CDMO事業で戦略的パートナーシップ契約
MDNT - significant increase, strategic partnership agreement with AGC in the cell therapy drug CDMO business.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.